Compare ESP & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | ASMB |
|---|---|---|
| Founded | 1928 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 512.1M |
| IPO Year | 1995 | 2010 |
| Metric | ESP | ASMB |
|---|---|---|
| Price | $62.26 | $22.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $52.00 |
| AVG Volume (30 Days) | 26.0K | ★ 292.3K |
| Earning Date | 09-23-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | 28.81 | ★ 91.78 |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $46,124,325.00 | N/A |
| Revenue This Year | $13.61 | N/A |
| Revenue Next Year | $5.53 | N/A |
| P/E Ratio | $16.63 | ★ N/A |
| Revenue Growth | ★ 4.95 | N/A |
| 52 Week Low | $36.00 | $21.80 |
| 52 Week High | $74.77 | $39.71 |
| Indicator | ESP | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 27.24 |
| Support Level | $60.47 | $21.80 |
| Resistance Level | $67.31 | $30.36 |
| Average True Range (ATR) | 2.53 | 1.22 |
| MACD | -0.26 | -0.41 |
| Stochastic Oscillator | 33.73 | 1.75 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.